Upadacitinib Approved for Nonradiographic Axial Spondyloarthritis

The U.S. Food and Drug Administration (FDA) granted approval to upadacitinib for the treatment of patients with active nonradiographic axial spondyloarthritis (nr-axSpA) on October 21, 2022.

Based on the findings of the Phase 3 SELECT-AXIS 2 clinical trial including 314 adults with active nr-axSpA, patients who received upadacitinib 15 mg (44.9%) showed improved disease activity compared to patients who received a placebo (22.3%) for their disease management. In addition to efficacy and tolerability, upadacitinib 15 mg demonstrated a safety profile similar to that among patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

—Priyam Vora

Reference:
AbbVie. RINVOQ® (Upadacitinib) receives its sixth U.S. FDA approval. Press release. October 21, 2022.

https://news.abbvie.com/news/press-releases/rinvoq-upadacitinib-receives-its-sixth-us-fda-approval.htm